Lonza - PBMCs

Pharma Exclusives Pressreleases

Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa

Tuesday, September 23, 2025

Longeveron Inca clinical stage biotechnology company developing cellular therapies for lifethreatening rare pediatric and chronic agingrelated conditions today announced that it will participate in the Alliance for Regenerative Medicines Cell Gene M...

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Monday, September 08, 2025

Cybin Inc a clinicalstage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative nextgeneration treatment options today announced completion of enrollment

Allergan Aesthetics Launches Campaign to Educate Consumers about Hyaluronic Acid (HA) Injectable Fillers

Wednesday, September 03, 2025

Allergan Aesthetics an AbbVie company has launched the Naturally You with Injectable Hyaluronic Acid Fillers campaign aimed to providing clear factual education about HA injectable fillers

BD Expands Peripheral Artery Disease Awareness Efforts with 'Love Your Limbs' Community Screening Initiative

Tuesday, September 02, 2025

In recognition of Peripheral Artery Disease PAD Awareness Month BD Becton Dickinson and Company NYSE BDX is shining a spotlight on a serious yet often overlooked circulatory disorder that restricts

Merck’s Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study

Tuesday, September 02, 2025

Merckknown as MSD outside of the United States and Canada today announced positive topline results from the Phase CORALreef Lipids trial evaluating the safety and efficacy of enlicitide decanoate an investigational

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

Friday, August 29, 2025

Teva Pharmaceuticals Inc a US affiliate of Teva Pharmaceutical Industries Ltd NYSE and TASE TEVA announced today the FDA approval and US launch of a generic version of Saxenda liraglutide injection

Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2

Thursday, August 28, 2025

Moderna Inctoday announced that the US Food and Drug Administration FDA has approved the supplemental Biologics License Applications sBLA for the formulas for Spikevax and mNEXSPIKE

AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

Monday, August 25, 2025

AbbVieand Gilgamesh Pharmaceuticals Inc Gilgamesh today announced a definitive agreement under which AbbVie will acquire Gilgameshs lead investigational candidate currently in clinical development

Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform

Friday, August 22, 2025

Kite a Gilead Company today announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics a privately held biotechnology company developing in vivo CAR therapeutics for million

Thermo Fisher Scientific Opens Manufacturing Center of Excellence Site in North Carolina

Friday, August 22, 2025

Thermo Fisher Scientific Inc the world leader in serving science today announced the grand opening of its innovative manufacturing center of excellence facility in Mebane NC The new squarefoot carbon neutral site